Tiotropium for the treatment of adolescents with moderate to severe symptomatic asthma


The role of Tiotropium ( Spiriva ) for the treatment of adolescents with asthma has not yet been clearly defined. A study has assessed the efficacy and safety of inhaled Tiotropium in adolescents with moderate to severe symptomatic asthma.

Randomized, placebo-controlled trials were included in this systematic review. Primary outcomes were peak and trough forced expiratory volume in 1 second ( FEV1 ).

Three studies ( approximately 1,000 patients ) were included. Tiotropium was associated with significant improvements in FEV1 peak ( mean change from baseline ) by 120 mL ( P less than 0.001 ) and trough by 100 mL ( P less than 0.001 ) compared with placebo.

Tiotropium has significantly reduced the percentage of patients who experienced an Asthma Control Questionnaire 7 worsening episode defined as a change from trial baseline of 0.5 points or more compared with placebo ( 2.1% vs 4.8%, number needed to treat, NNT= 38 ) and also was associated with a significantly decreased in the number of patients with at least one exacerbation compared with placebo ( 17.6 vs 23.8%, NNT=16 ).

Finally, no significant differences were found in rescue medication use, withdrawals, withdrawals due to adverse events, adverse events ( 27.3% vs 27.1% ), and serious adverse reactions ( 6.5% vs 7.1% ). Tiotropium in doses of 2.5 mcg once daily or 5.0 mcg once daily resulted in equivalent effects.

In conclusion, Tiotropium was well tolerated and efficacious as an addition to maintenance treatment with an inhaled corticosteroid or an inhaled corticosteroid plus a long-acting beta-agonist in adolescents with moderate to severe asthma.
Available data do not suggest an advantage of the 5-mcg once-daily dose ( used in adults ) compared with the 2.5-mcg once-daily dose of Tiotropium. ( Xagena )

Rodrigo GJ, Castro-Rodríguez JA, Ann Allergy Asthma Immunol 2015;115:211-216

XagenaMedicine_2015



Indietro

Altri articoli

Antibodies against the IL-5 pathway have been developed for the treatment of late-onset eosinophilic corticosteroid-resistant asthma. However, the prevalence of...


The European Commission has approved Dupixent ( Dupilumab ) for use in adults and adolescents 12 years and older as...


Dupilumab ( Dupixent ), a fully human VelocImmune-derived anti-interleukin-4 ( IL-4 ) receptor alpha monoclonal antibody, inhibits signaling of IL-4...


The FDA ( U.S. Food and Drug Administration ) has approved Dupixent ( Dupilumab ) for use with other medicines...


The European Commission has approved a label update for the use of once-daily Relvar Ellipta ( Fluticasone furoate / Vilanterol,...


FDA ( U.S. Food and Drug Administration ) has approved Inbrija ( Levodopa inhalation powder ) for intermittent treatment...


A study has examined prenatal Paracetamol ( Acetaminophen [ N-acetyl-p-aminophenol ]; APAP ) exposure in relation to language development in...


Few studies have systematically investigated insomnia in adults with epilepsy. Researchers have performed a prospective cross-sectional investigation of the prevalence, severity,...



Asthma exacerbations are commonly precipitated by viral upper respiratory infections ( URIs ). Vitamin D insufficiency associates with susceptibility to...